22nd Century Plans Reverse Stock Split to Restore NASDAQ Compliance
ByAinvest
Monday, Jun 16, 2025 9:53 pm ET1min read
ERNA--
The reverse stock split will reduce the number of authorized and outstanding shares proportionally. This move will not significantly alter stockholders' percentage ownership or voting power, as the company aims to maintain the current distribution of shares among shareholders. Options and warrants will be adjusted accordingly to reflect the new share structure.
The company's decision to implement a reverse stock split comes after its stock price fell below the NASDAQ minimum bid price requirement of $1.00 per share. This strategic move is part of a broader effort to strengthen the company's financial foundation and maintain access to capital markets, which are crucial for advancing its clinical programs.
The reverse stock split was approved by the company's shareholders, indicating support for management's strategy. However, some investors may view the move as a sign of financial instability, as it often signals that a company is struggling to meet its listing requirements.
For more information about the reverse stock split, stockholders can refer to the company's definitive proxy statement filed with the Securities and Exchange Commission (SEC) on April 14, 2025, which is available at www.sec.gov and on the company's website at www.investor.22ndcenturygroup.com/financials/sec-filings.
References:
[1] https://www.nasdaq.com/articles/ernexa-therapeutics-announces-1-15-reverse-stock-split-regain-nasdaq-compliance
XXII--
22nd Century Group plans a 1-for-23 reverse stock split to regain NASDAQ compliance. The split will take effect on June 20, 2025, and reduce the number of authorized and outstanding shares proportionally. Stockholders' percentage ownership and voting power will remain largely unchanged, and options and warrants will be adjusted accordingly. The reverse split is aimed at restoring the company's NASDAQ listing.
22nd Century Group, a biotechnology company specializing in innovative stem cell therapies, has announced a 1-for-23 reverse stock split to regain compliance with NASDAQ's listing requirements. The split, scheduled to take effect on June 20, 2025, aims to restore the company's NASDAQ listing and ensure it meets the exchange's minimum bid price requirement.The reverse stock split will reduce the number of authorized and outstanding shares proportionally. This move will not significantly alter stockholders' percentage ownership or voting power, as the company aims to maintain the current distribution of shares among shareholders. Options and warrants will be adjusted accordingly to reflect the new share structure.
The company's decision to implement a reverse stock split comes after its stock price fell below the NASDAQ minimum bid price requirement of $1.00 per share. This strategic move is part of a broader effort to strengthen the company's financial foundation and maintain access to capital markets, which are crucial for advancing its clinical programs.
The reverse stock split was approved by the company's shareholders, indicating support for management's strategy. However, some investors may view the move as a sign of financial instability, as it often signals that a company is struggling to meet its listing requirements.
For more information about the reverse stock split, stockholders can refer to the company's definitive proxy statement filed with the Securities and Exchange Commission (SEC) on April 14, 2025, which is available at www.sec.gov and on the company's website at www.investor.22ndcenturygroup.com/financials/sec-filings.
References:
[1] https://www.nasdaq.com/articles/ernexa-therapeutics-announces-1-15-reverse-stock-split-regain-nasdaq-compliance
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet